目的 :研究无创参数SpO_2/FiO_2(S/F)和PaO_2/FiO_2(P/F)之间的关系,探索使用无创参数辨识急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)患者疾病严重程度的可能性。方法:访问重症医学信息数据库(Medical Information ...目的 :研究无创参数SpO_2/FiO_2(S/F)和PaO_2/FiO_2(P/F)之间的关系,探索使用无创参数辨识急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)患者疾病严重程度的可能性。方法:访问重症医学信息数据库(Medical Information Mart for Intensive Care,MIMIC-Ⅲ),获取患者相关生理参数,将患者数据随机分为训练集和测试集。使用训练集,利用广义线性回归模型,建立lg(S/F)与lg(P/F)之间的线性关系,选择最优的回归方程作为对数线性回归模型,并将lg(S/F)与lg(P/F)之间的线性关系和S/F与P/F之间的线性关系进行对比研究。使用测试集,比较2种模型对于P/F在100(重度ARDS)、200(中度ARDS)、300(轻度ARDS)处的辨识效果。结果:在训练集(n=61 634)上推导出lg(P/F)与lg(S/F)之间的线性关系:lg(S/F)=1.277+0.437×lg(P/F)(r=0.66,P<0.000 1),并确定了P/F在100、200、300处对应的S/F阈值为131、201、271。在测试集(n=26 758)上使用S/F阈值验证了其辨识效果,且较传统线性回归模型辨识结果有了明显改善。结论:通过研究,认为在患者血气分析结果缺失的情况下,可以使用无创参数SpO_2/FiO_2代替PaO_2/FiO_2作为ARDS患者病情诊断的辅助手段。展开更多
Background: Recombinant human soluble thrombomodulin (rhTM) was approved for the treatment of disseminated intravascular coagulation in Japan, and rhTM has anti-inflammatory effects. Disordered coagulation is a part o...Background: Recombinant human soluble thrombomodulin (rhTM) was approved for the treatment of disseminated intravascular coagulation in Japan, and rhTM has anti-inflammatory effects. Disordered coagulation is a part of the acute respiratory distress syndrome (ARDS) pathophysiology and thus we hypothesize that anticoagulant therapy may help. This preliminary study was to observe the safety of rhTM administration and the improvement on biomarker levels after the therapy for ARDS-patients. Objectives: Case series of ARDS-patients. Methods: Seventeen ARDS-patients that required ventilatory management were treated with rhTM and clinical and laboratory data were collected including platelets, thrombin-antithrombin complex (TAT), fibrinogen degradation products, oxygen saturation/the fraction of inspired oxygen (SpO2/FIO2), and high-mobility group-1 (HMG-1). The administration of rhTM was started during 6 days at a bolus dose of 0.06 mg/kg/day immediately after the diagnosis of ARDS. Results: Eleven of the 17 ARDS-patients were alive at 28 days after the beginning of the administration of rhTM. The serial pattern of the SpO2/FIO2 showed remarkable differences between the survivors and nonsurvivors from day 5 to day 7. The TAT in the survivors significantly decreased after treatment, and there were significantly lower levels in the TAT on day 7 in comparison to that of the nonsurvivors. The serial changes of HMG-1 showed increased levels in the nonsurvivors until day 5 after the administration of rhTM. Conclusions: Additional rhTM administration can safely improve the parameters in survival ARDS-patients, as demonstrated by significant improvements in the SpO2/FIO2, HMG-1 and TAT.展开更多
文摘目的 :研究无创参数SpO_2/FiO_2(S/F)和PaO_2/FiO_2(P/F)之间的关系,探索使用无创参数辨识急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)患者疾病严重程度的可能性。方法:访问重症医学信息数据库(Medical Information Mart for Intensive Care,MIMIC-Ⅲ),获取患者相关生理参数,将患者数据随机分为训练集和测试集。使用训练集,利用广义线性回归模型,建立lg(S/F)与lg(P/F)之间的线性关系,选择最优的回归方程作为对数线性回归模型,并将lg(S/F)与lg(P/F)之间的线性关系和S/F与P/F之间的线性关系进行对比研究。使用测试集,比较2种模型对于P/F在100(重度ARDS)、200(中度ARDS)、300(轻度ARDS)处的辨识效果。结果:在训练集(n=61 634)上推导出lg(P/F)与lg(S/F)之间的线性关系:lg(S/F)=1.277+0.437×lg(P/F)(r=0.66,P<0.000 1),并确定了P/F在100、200、300处对应的S/F阈值为131、201、271。在测试集(n=26 758)上使用S/F阈值验证了其辨识效果,且较传统线性回归模型辨识结果有了明显改善。结论:通过研究,认为在患者血气分析结果缺失的情况下,可以使用无创参数SpO_2/FiO_2代替PaO_2/FiO_2作为ARDS患者病情诊断的辅助手段。
文摘Background: Recombinant human soluble thrombomodulin (rhTM) was approved for the treatment of disseminated intravascular coagulation in Japan, and rhTM has anti-inflammatory effects. Disordered coagulation is a part of the acute respiratory distress syndrome (ARDS) pathophysiology and thus we hypothesize that anticoagulant therapy may help. This preliminary study was to observe the safety of rhTM administration and the improvement on biomarker levels after the therapy for ARDS-patients. Objectives: Case series of ARDS-patients. Methods: Seventeen ARDS-patients that required ventilatory management were treated with rhTM and clinical and laboratory data were collected including platelets, thrombin-antithrombin complex (TAT), fibrinogen degradation products, oxygen saturation/the fraction of inspired oxygen (SpO2/FIO2), and high-mobility group-1 (HMG-1). The administration of rhTM was started during 6 days at a bolus dose of 0.06 mg/kg/day immediately after the diagnosis of ARDS. Results: Eleven of the 17 ARDS-patients were alive at 28 days after the beginning of the administration of rhTM. The serial pattern of the SpO2/FIO2 showed remarkable differences between the survivors and nonsurvivors from day 5 to day 7. The TAT in the survivors significantly decreased after treatment, and there were significantly lower levels in the TAT on day 7 in comparison to that of the nonsurvivors. The serial changes of HMG-1 showed increased levels in the nonsurvivors until day 5 after the administration of rhTM. Conclusions: Additional rhTM administration can safely improve the parameters in survival ARDS-patients, as demonstrated by significant improvements in the SpO2/FIO2, HMG-1 and TAT.
